The PASTEUR Act

The PASTEUR Act (HR8920) establishes a subscription-style payment model for novel antibiotics, aiming to incentivize research and development by guaranteeing a predictable revenue stream for successful drugs. This model addresses the current market failure where new antibiotics are under-developed due to low profitability, as they are used sparingly to prevent resistance. The bill was referred to multiple committees, indicating a broad scope of impact across healthcare, veterans' affairs, and defense, as antibiotic resistance is a national security concern. Funding for the subscription model will come from the federal government, likely through appropriations to agencies like the Department of Health and Human Services (HHS). Pharmaceutical companies with strong infectious disease pipelines, such as Pfizer ($PFE), Merck ($MRK), GlaxoSmithKline ($GSK), AstraZeneca ($AZN), Eli Lilly ($LLY), and Johnson & Johnson ($JNJ), are positioned to benefit from this guaranteed revenue. The mechanism involves HHS entering into contracts with drug developers for access to novel antibiotics, providing a fixed payment regardless of the volume of drugs sold. This shifts the financial incentive from sales volume to the public health value of the antibiotic. Historically, government incentives for drug development have shown mixed results. For example, the Orphan Drug Act of 1983 provided tax credits and market exclusivity for drugs treating rare diseases, leading to a significant increase in orphan drug development. While not directly comparable in mechanism, it demonstrates that targeted government intervention can stimulate pharmaceutical R&D. The Biomedical Advanced Research and Development Authority (BARDA) has also provided funding for antibiotic development, but the PASTEUR Act proposes a more direct and sustained market-shaping mechanism. There is no direct historical precedent for a 'subscription model' for antibiotics at this scale, making direct market comparisons difficult. Specific winners include pharmaceutical companies with active antibiotic research programs. Pfizer ($PFE) has a significant anti-infective portfolio. Merck ($MRK) is a leader in infectious disease. GlaxoSmithKline ($GSK) and AstraZeneca ($AZN) also have relevant R&D. Eli Lilly ($LLY) and Johnson & Johnson ($JNJ) maintain broad pharmaceutical interests that could pivot or expand into this incentivized area. Losers are not directly apparent, as the bill aims to create a market where one currently fails. The next step involves committee hearings and markups. The bill's broad referral suggests a lengthy legislative process, with potential for amendments and delays.